Julie Vose

Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival.

Adrian Wiestner, Hui Liu, Kazutaka Nakayama, 2007, Blood.

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.

D. Weisenburger, J. Vose, Julie Vose, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.

Kai Fu, Jan Delabie, Andreas Rosenwald, 2011, American journal of clinical pathology.